Editorial: Inhibiting PARP as a Strategic Target in Cancer (+links to published papers) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, May 20, 2016

Editorial: Inhibiting PARP as a Strategic Target in Cancer (+links to published papers)



open access

Apr. 15, 2016

 
The Editorial on the Research Topic

 This collection of articles addresses the role of PARP inhibition in cancer therapy, from both basic science and clinical research perspectives. The integration of bench and bedside aspects is vital for moving the field forward to the most efficacious use of these agents. While our knowledge of PARP inhibitors has grown substantially in a relatively short amount of time, critical issues, such as mechanisms of action, appropriate therapeutic combinations, limiting short- and long-term toxicity, and defining the ideal patient population, remain to be resolved. We have compiled these articles to stimulate thoughts and discussion regarding this promising line of therapy, and expedite the successful application to patients.


0 comments :

Post a Comment

Your comments?